Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1480-1483

  De Jong, R S ^a   Slijfer, E A M ^b   Uges, D R A ^b   Mulder, N H ^a   De Vries, E G E ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alkaline phosphatase; Bile; Etoposide phosphate; Gastric juice; Pharmacology; Prodrug

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC ALKALOID; ETOPOFOS; PRODRUG;

ARTICLE; BILE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH JUICE;

EID: 0030777511     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.581     Document Type: Article

References (15)

1. Davenport HW (1977) Physiology of the Digestive Tract. Year Book Medical Publishers: Chicago
2. De Jong RS, Mulder NH, Dijksterhuis D and De Vries EGE (1995) Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 15: 2319-2330
3. De Jong RS, Mulder NH, Uges DRA, Kaul S, Winograd B, Sleijfer DTh, Groen HJM, Willemse PHB, van der Graaf WTA, de Vries EGE (1997) Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer 75: 1660-1666
4. Fallinghorg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K and Rasmussen HH (1989) pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 3: 605-613
5. Hande KR, Krozely MG, Greco FA, Hainsworth JD and Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374-377
6. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A and Wrigley PFM (1985) Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21: 1315-1319
7. Holthuis JJM, Van Oort WJ and Pinedo HM (1981) A sensitive high-performance liquid Chromatographic method for determination of the anti-neoplastic agents VP 16-213 and VM 26 in biological fluids. Anal Chim Acta 130: 23-30
8. Joel SP, Clark PI and Slevin ML (1995) Stability of the i.v. and oral formulations of etoposide in solution. Cancer Chemother Pharmacol 37: 117-124
9. Moss DW, Henderson AR and Kachmar JF (1986) Enzymes. In: Textbook of Clinical Chemistry. Tietz NW (ed), pp. 704-717. WB Saunders: Philadelphia
10. Saulnier MG, Langley DR, Kadow JF, Senter PD, Knipe JO, Tun MM, Vyas DM and Doyle TW (1994) Synthesis of etoposide phosphate. BMY-40481: a water-soluble clinically active prodrug of etoposide. Bioorg Med Chem Lett 4: 2567-2572
11. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellström I, Hellström KE (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85: 4842-4846
12. Sessa C, Zuchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, Prins C, Schacter L, Winograd B and D'Incalci M (1995) Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13: 200-209
13. Shah JC. Chen JR and Chow D (1989) Preformulalion study of etoposide: Identification of physiological characteristics responsible for the low and erratic bioavailability of etoposide. Pharm Res 6: 408-412
14. Shevde K and Trivedi N (1991) Effects of clear liquids on gastric volume and pH in healthy volunteers. Anesth Analg 72: 528-531
15. Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ and Wrigley PFM (1989) The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24: 329-331